1982
Amy Abernethy says her first real job, in 1982, was in an artificial intelligence lab at NASA.
“That was where my first real job was in 1982. And so that's a long time ago.”
Topic
Amy Abernethy is a physician and researcher who appears on two podcasts, The Long Run with Luke Timmerman and Raising Health from a16z, discussing her career in clinical trials, health data and regulation. On The Long Run, she described work in Australia from 1999 to 2003, the Duke Cancer Care Research Program she launched in 2004, and her 2009 white paper on a rapid learning system for cancer.
On Raising Health, she said testing the mRNA vaccines used clinical trial methods from around 1995. She also described her work at the FDA on letting companies push data directly to the agency. She told the same podcast that her first real job, in 1982, was in an artificial intelligence lab at NASA.
19 facts from 2 episodes, in date order. These are what speakers said on the shows, each linked to the moment it was said. They aren't independently verified.
1982
Amy Abernethy says her first real job, in 1982, was in an artificial intelligence lab at NASA.
“That was where my first real job was in 1982. And so that's a long time ago.”
1995
Amy Abernethy says that testing the mRNA vaccines used clinical trial methods from around 1995, with little innovation in trial design.
“we hit the wall of evidence generation where we went back to circa 1995 clinical trials to actually try and understand which of the mRNA vaccines worked for whom and when.”
1999-2003
The Duke Clinical Research Institute ran large-scale clinical trials that included sites in Australia, which Abernethy used to learn clinical trial development.
“at that time, the DCRI had large-scale clinical trials, including sites in Australia.”
1999-2003
Amy Abernethy worked in Australia from 1999 to 2003 as a U.S. physician and researcher.
“during this period of time, which was 1999 to 2003, I was there as a rogue U.S. physician in Australia”
2000s
Abernethy's Australian cancer pain trial built its data set from Medicare, hospital systems and insurers in Australia.
“we sourced the data set for the trial from the data sets available from Medicare in Australia, from the hospital systems in Australia, from the insurers in Australia.”
2000s
The factorial randomized trial of three cancer pain interventions was deployed across the state of South Australia.
“we deployed those different interventions at scale across the state of South Australia.”
2004
Starting in 2004, Amy Abernethy launched the Duke Cancer Care Research Program, initially just a sticker on her door and business cards.
“starting in 2004, I became the Duke Cancer Care Research Program, which was nothing more than a sticker on my door and a few business cards.”
2009
In 2009 Abernethy wrote a white paper on a rapid learning system for cancer.
“I had written a treatise in 2009 about this idea of what we call a rapid learning system for cancer.”
2009
Abernethy's white paper became CancerLink, which the American Society of Clinical Oncology funded.
“That white paper ultimately became something with an oncology that's known as CancerLink. It got funded by the American Society of Clinical Oncology”
2009
In 2009 Abernethy's group received a National Cancer Institute grant to extract data from unstructured documents using natural language processing and other techniques.
“In 2009, we had a grant from the National Cancer Institute to try and figure out how to solve for this.”
2011
Around 2011-2012, Abernethy, Rob Califf and another colleague started the Center for Learning Healthcare at Duke, an incubator for using data and technology to speed research.
“together with Rob Califf, who subsequently becomes the commissioner of the FDA, and Victor Zhao, who's currently the president of the National Academy of Medicine, we started something called the Center for Learning Healthcare at Duke.”
2011
Abernethy argues commercial and venture investors were not ready for this kind of health data work until around 2011-2012, when enough electronic health records existed.
“I would argue that the private or commercial side, even the venture side, was not ready for all of this until circa 2011, 2012”
Undated
Amy Abernethy attended Duke's TIP summer program in the second cohort of its residential program.
“I was a part of the second cohort ever to go to TIP as a part of their residential program.”
Undated
Amy Abernethy's mother wrote a nursing textbook called Dosage Calculations, and Abernethy helped edit it and do its math problems as a child.
“my mom had written a textbook for nurses called Dosage Calculations”
Undated
Amy Abernethy sits on the board of directors of athenahealth, which runs a cloud-based electronic health record used across the U.S.
“So I sit on the board of directors of Athena Health.”
Undated
Amy Abernethy says using AI to identify drug targets creates little regulatory worry because the work happens before a molecule is put into people.
“there's some parts of the application of AI in the healthcare and life sciences landscape that don't really create a bunch of angst. Identification of targets is a good example of that.”
Undated
Amy Abernethy says that while at the FDA she worked on infrastructure so companies could push data directly to the agency instead of submitting lengthy reports.
“we were building the pipes at FDA to be ready for a landscape where really all you do is push your data across over FDA and FDA is ready to receive”
Undated
Amy Abernethy proposes that a foundation model for reading chest X-rays could be regulated once, so specialized models built on it need less review.
“a foundational model of reading a chest X-ray. And then that's already done, a check for the foundational model.”
Undated
Amy Abernethy says statistical programs written 10 to 15 years ago began targeting clinical trial monitors' work at higher-risk sites, which became risk-based monitoring.
“pattern recognition and statistical programs were written about 10, 15 years ago to start to do that and better target the work of monitors.”
Episodes